Compositions and Methods for the Innate Immune Response Pathway

Autoimmune diseases are the consequence of complex interactions between a mosaic of host genetic factors and etiologic elements. Celiac disease (CD) is an autoimmune disease prevalent in 1% of the general population, but is unique on two accounts; a) the majority (90%) of individuals with CD have the HLA class II DQ2 allele, the others HLA-DQ8 and b) the etiologic agent is gluten proteins from wheat and related prolamins in barley and rye. The disease process is generally considered to be mediated by T cells that recognize HLA-DQ2 specific peptide sequences in gluten. There is currently no therapeutic treatment for CD. To this end, the inventors have identified a novel therapeutic target for CD and innate immune pathways in other inflammatory conditions.

Attached files:
US 20090311214.jpg

Patents:
US 20,090,311,214

Inventor(s): MANN DEAN L [US]; HARRIS KRISTINA M [US]

Type of Offer: Licensing



Next Patent »
« More Biotech Patents

Share on      


CrowdSell Your Patent